Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company, announced today that preliminary findings from its ongoing Phase II dermatological study show topical treatment with AVR118 appears to have clinical activity in reducing inflammation and redness associated with surgical incisions or dermatologic dermabrasion.

The Phase II open label dermatological study is evaluating the activity of a topically applied spray formulation of AVR 118 as an anti-inflammatory and regenerative healing agent. The first cohort of patients examined underwent dermabrasion for the treatment of severe acne. Following the procedure, AVR118 was applied directly to one half of the inflamed facial tissue. The other half of the face remained untreated. A preliminary examination of five patients demonstrated visible improvement on the treated side of their face. The treated area showed less inflammation as well as a reduction in the redness and swelling of acne lesions.

The second cohort of patients examined underwent plastic surgery that resulted in a minimum of two bilateral surgical incisions. AVR118 was applied topically to one wound and the second wound served as an untreated control. In early results from two patients, one patient demonstrated a decrease in inflammation on the treated side.

"I am very encouraged by this data. The response we've seen thus far indicates that AVR118 may have beneficial activity in both sets of patients," said Stephen M. Elliston, President and Chief Executive Officer. "A preliminary and unexpected result was the reduction of the inflammatory symptoms of acne. We plan to amend the protocol to include patients being treated solely for acne, given the potential of this market," added Elliston.

Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com.

Contact

The Signature Agency
Gayle Challinor, 800-870-8700/919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939

Posted: June 2007

View comments

Hide
(web5)